Intelligence Search Intelligence Filter by: Industry Team Airport & AviationAutomotiveEmerging TechnologiesEnergy Food & BeverageHealth CareHospitality, Resort & GolfInsurance & Reinsurance Life SciencesMedical DevicesSports Practice Area Business Law All Business LawEmployee Benefits & Executive CompensationEnvironmental RegulationEstates & TrustsFinance & Financial InstitutionsHealth Care Finance Private Equity & Venture CapitalPublic FinanceReal EstateSecurities, Commodities & Exchange RegulationTaxationTransactional & Securities Government & Public Policy All Government & Public PolicyFDA RegulatoryFederal & State Energy RegulatoryGovernment ProcurementImmigration, Nationality & Consular Law NHTSA & Motor Vehicle SafetyPolitical LawPublic PolicySurface Transport Intellectual Property All Intellectual PropertyBusiness Method & Software PatentsChemical, Biotechnology & PharmaceuticalElectronicsGreen Energy TechnologiesInformation Technology & Outsourcing IP Due DiligenceIP LitigationMechanical & Electromechanical TechnologiesPatent Office TrialsTrademark, Copyright & Advertising Counseling International All InternationalChina EuropeJapan Litigation All LitigationAntitrustAppellateBankruptcy & Business ReorganizationsBusiness Litigation & Dispute ResolutionConstructionConsumer Financial Services Distribution & FranchiseGovernment Enforcement, Compliance & White Collar DefenseInsurance & Reinsurance LitigationLabor & EmploymentPrivacy, Security & Information ManagementSecurities Enforcement & LitigationTrade Secret Noncompete Litigation Topic Accountable Care OrganizationsAmerica Invents Act (Patent Reform)Consumer Protection Act Corporate GovernanceDodd–Frank Wall Street ReformExport Control/Economic Sanctions Foreign Corrupt Practices Act (FCPA)Health Care ReformPersonalized Medicine Type ArticleBlog Post BookNewsletter VideoWhite Paper Featured All Filters applied: Search phrase entered: Sort results by: Most Recent Most Viewed Most Shared Foley Blogs: CFSL Bulletin Cleantech & Nano Dashboard Insights Labor & Employment Law Perspectives Personalized Medicine Bulletin PharmaPatents Renewable Energy Outlook Wisconsin Appellate Law 12next En Banc Federal Circuit Eases Requirements for Induced Infringement of Method Claims 04 September 2012 PharmaPatents On August 31, 2012, the Federal Circuit issued an en banc, per curiam opinion deciding both Akamai Technologies, Inc. v. Limelight Networks, Inc. and McKesson Technologies,... Deja Vu All Over Again in Federal Circuit's August 16 Myriad Decision 17 August 2012 PharmaPatents On August 16, 2012, just four weeks after it heard oral arguments, the Federal Circuit issued its second decision in Association for Molecular Pathology v. Myriad... USPTO Issues Prometheus Examination Guidelines 09 July 2012 PharmaPatents On July 3, 2012, the USPTO issued its 2012 Interim Procedure for Subject Matter Eligibility Analysis 0f Process Claims Involving Laws of Nature. According to the... What Do The IP Lawyers Have To Say In The Myriad Remand? 27 June 2012 PharmaPatents Several associations and organizations of intellectual property lawyers submitted amicus briefs in the Federal Circuit remand of Association for Molecular Pathology... The Myriad And ACLU Supplemental Briefs On Remand To The Federal Circuit 22 June 2012 PharmaPatents Myriad and the ACLU filed their supplemental briefs in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU “gene patenting”/BRCA1... Eli Lilly Suggests Bright-Line Rule In Myriad Amicus Brief 20 June 2012 PharmaPatents Eli Lilly filed an interesting amicus brief in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case).... The United States Files Its Amicus Brief In Myriad 18 June 2012 PharmaPatents The briefs in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case) were due last Friday, June 15,... Federal Circuit Sets Briefing Deadline, Oral Argument Date For Myriad Isolated DNA Case 01 May 2012 PharmaPatents Pursuant to the Supreme Court’s March 26, 2012 order remanding Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI... Vlog: Why Prometheus Doesn't Govern Myriad But Might Impact It Anyway 30 April 2012 PharmaPatents I was honored to be invited by the Washington Legal Foundation to prepare a video commentary on the recent Supreme Court decision in Prometheus and its possible... Newsletter for Leaders in the Medical Device Industry – October 2011 02 November 2011 Legal News: Medical Devices The New Patent Law: The Rules Have Changed, Your IP Strategies Must Also Change By Barry L. Grossman (bgrossman@foley.com) As of September 16, 2011, the rules... 12next Related 1 2 3
En Banc Federal Circuit Eases Requirements for Induced Infringement of Method Claims 04 September 2012 PharmaPatents On August 31, 2012, the Federal Circuit issued an en banc, per curiam opinion deciding both Akamai Technologies, Inc. v. Limelight Networks, Inc. and McKesson Technologies,...
Deja Vu All Over Again in Federal Circuit's August 16 Myriad Decision 17 August 2012 PharmaPatents On August 16, 2012, just four weeks after it heard oral arguments, the Federal Circuit issued its second decision in Association for Molecular Pathology v. Myriad...
USPTO Issues Prometheus Examination Guidelines 09 July 2012 PharmaPatents On July 3, 2012, the USPTO issued its 2012 Interim Procedure for Subject Matter Eligibility Analysis 0f Process Claims Involving Laws of Nature. According to the...
What Do The IP Lawyers Have To Say In The Myriad Remand? 27 June 2012 PharmaPatents Several associations and organizations of intellectual property lawyers submitted amicus briefs in the Federal Circuit remand of Association for Molecular Pathology...
The Myriad And ACLU Supplemental Briefs On Remand To The Federal Circuit 22 June 2012 PharmaPatents Myriad and the ACLU filed their supplemental briefs in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU “gene patenting”/BRCA1...
Eli Lilly Suggests Bright-Line Rule In Myriad Amicus Brief 20 June 2012 PharmaPatents Eli Lilly filed an interesting amicus brief in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case)....
The United States Files Its Amicus Brief In Myriad 18 June 2012 PharmaPatents The briefs in the remand of Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI case) were due last Friday, June 15,...
Federal Circuit Sets Briefing Deadline, Oral Argument Date For Myriad Isolated DNA Case 01 May 2012 PharmaPatents Pursuant to the Supreme Court’s March 26, 2012 order remanding Association for Molecular Pathology v. Myriad Genetics, Inc. (the ACLU ”gene patenting”/BRCAI...
Vlog: Why Prometheus Doesn't Govern Myriad But Might Impact It Anyway 30 April 2012 PharmaPatents I was honored to be invited by the Washington Legal Foundation to prepare a video commentary on the recent Supreme Court decision in Prometheus and its possible...
Newsletter for Leaders in the Medical Device Industry – October 2011 02 November 2011 Legal News: Medical Devices The New Patent Law: The Rules Have Changed, Your IP Strategies Must Also Change By Barry L. Grossman (bgrossman@foley.com) As of September 16, 2011, the rules...